MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

In the study cohort, 2,310 patients died during a median follow-up of 6.3 years, and prostate cancer accounted for 454 (19.7% ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...